Patient characteristics and data
| Patient characteristics (n=52) | Subcategory | ||
| Anti-VEGF treatment | None | PDR group | n=28 |
| <1 week before surgery | Bevacizumab 1 group | n=17 | |
| >4 weeks before surgery | Bevacizumab 2 group | n=7 | |
| Age (mean±SD) | 53.2±14.2 years | ||
| Gender | Male | n=32 | |
| Female | n=20 | ||
| Diabetes type | Type I | n=19 | |
| Type II | n=33 | ||
| Degree of fibrosis | No fibrosis (0) | n=10 | |
| Only few preretinal membranes (1) | n=3 | ||
| Some proliferative membranes (2) | n=27 | ||
| Abundant proliferative membranes (3) | n=12 | ||
| Haemorrhage | No haemorrhage (0) | n=8 | |
| Haemorrhage (1) | n=44 | ||
| CTGF (geometric mean, 95% CI) | 12.4 ng/ml (10.8–14.2) | ||
| VEGF (geometric mean, 95% CI) | 121.9 pg/ml (66.4–223.9) | ||
| Ratio CTGF/log10(VEGF) (geometric mean, 95% CI) | 6.7 (5.3–8.4) | ||
CTGF, connective tissue growth factor; PDR, proliferative diabetic retinopathy; VEGF, vascular endothelial growth factor.